KLOXXADO® Nasal Spray Now Offers Longer Shelf Life and Higher Naloxone Dose

The international pharmaceutical business Hikma Pharmaceuticals PLC has announced that KLOXXADO® (naloxone HCl) nasal spray 8mg would now have a longer shelf life of 36 months instead of 24. The 36-month dating system for KLOXXADO® packaging has been revised, having effect from March 2024 for products manufactured.

KLOXXADO® is a ready-to-use nasal spray that reverses the symptoms of an opioid overdose by containing twice as much naloxone per spray as Narcan® Nasal Spray 4mg. This treatment option is crucial in combating the overdose pandemic.

It has long been known that naloxone is a crucial, secure, and successful medication in the battle against opioid overdose.3. Organisations like the CDC4, the American Medical Association5, and others have observed that a greater dose of naloxone may be necessary to resuscitate a patient suffering from poisoning from illegal fentanyl or other opioids due to the rising incidence of illicitly made synthetic opioids. KLOXXADO® offers a crucial life-saving treatment option as a ready-to-use nasal spray with twice the amount of naloxone per spray as Narcan® Nasal Spray 4mg.

Dr. Hafrun Fridriksdottir, President of Hikma Generics, stated, "The shelf-life extension is good news for frontline responders and the thousands of people who carry KLOXXADO® and who may need to use it at a moment's notice to reverse an overdose." "We are happy to be providing a critical medication that can prevent fatal overdoses and save lives as we approach National Overdose Awareness Day on August 31st. We have a role to play in the fight against illicit fentanyl."